The results of this study clearly indicate that EGCG, a GTC, effectively prevents the development of hepatic preneoplastic lesions, which manifest as GST-P-positive foci, in our rat model of NAFLD/NASH-related liver tumorigenesis. The gene discussed is GSTP1; the disease is metabolic dysfunction-associated steatotic liver disease.